LifeStance Health Group (NASDAQ:LFST) Given New $7.00 Price Target at Barclays

LifeStance Health Group (NASDAQ:LFST) had its price objective boosted by equities research analysts at Barclays from $6.00 to $7.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has an “underweight” rating on the stock. Barclays‘s price target suggests a potential downside of 5.41% from the stock’s current price.

Separately, UBS Group decreased their price target on shares of LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating on the stock in a research note on Thursday, August 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.42.

LifeStance Health Group Stock Up 0.1 %

Shares of LFST stock opened at $7.40 on Monday. The company’s fifty day simple moving average is $6.96 and its two-hundred day simple moving average is $6.22. LifeStance Health Group has a 52 week low of $4.64 and a 52 week high of $9.20. The stock has a market cap of $2.83 billion, a P/E ratio of -28.46 and a beta of 1.24. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 0.20.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.67% and a negative net margin of 7.90%. The company had revenue of $312.70 million during the quarter, compared to analyst estimates of $302.25 million. During the same period in the prior year, the company earned ($0.17) earnings per share. The firm’s revenue was up 18.9% on a year-over-year basis. Analysts predict that LifeStance Health Group will post -0.22 EPS for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In related news, insider Ann Varanakis sold 5,269 shares of LifeStance Health Group stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $6.28, for a total transaction of $33,089.32. Following the completion of the transaction, the insider now directly owns 263,007 shares of the company’s stock, valued at approximately $1,651,683.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. ProShare Advisors LLC lifted its stake in shares of LifeStance Health Group by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 19,069 shares of the company’s stock worth $118,000 after acquiring an additional 1,500 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of LifeStance Health Group by 43.4% during the first quarter. Bessemer Group Inc. now owns 9,143 shares of the company’s stock worth $56,000 after purchasing an additional 2,768 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of LifeStance Health Group by 27.0% during the second quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock valued at $71,000 after purchasing an additional 3,063 shares during the period. SG Americas Securities LLC increased its stake in LifeStance Health Group by 8.7% in the 1st quarter. SG Americas Securities LLC now owns 44,925 shares of the company’s stock worth $277,000 after buying an additional 3,600 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in LifeStance Health Group by 12.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 42,366 shares of the company’s stock worth $262,000 after acquiring an additional 4,681 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.